Sponsored by: Miller Legal LLP

Find out if you qualify for a lawsuit

Contact Us:
(888) 775-3026(888) 775-3026

Januvia® Cancer Lawsuit

Our attorneys are currently investigating potential Januvia cancer lawsuits on behalf of diabetes patients that are diagnosed with pancreatic cancer and who have a history of taking Januvia (sitagliptin). Studies have shown that it is quite possible that Januvia increases a person's risk for developing pancreatic cancer.

There were almost 300 cases of pancreatic cancer in patients using Januvia and other similar drugs reported to the U.S. Food and Drug Administration (FDA) between Jan. 1, 2010 and June 30, 2012. This number far exceeds the number of cases reported by users of other diabetes medications, according to the group Public Citizen.

The Director of Public Citizen's Health and Research Group, Dr. Sideny Wolfe, issued a statement in March 2013 that discussed the risk of precancerous changes in the pancreases of people who took Januvia, Byetta (exenatide) and Victoza (liraglutide). In the statement, Dr. Wolfe talks about a study conducted by two doctors at UCLA that was published in the journal "Diabetes."

The group is now urging the FDA to ban use of these drugs. Our attorneys have taken a special interest into the link between Januvia and pancreatic cancer. This form of cancer is very deadly as the signs and symptoms usually do not show up until the cancer is already in an advanced stage, making treatment difficult.

If you or someone you love has been diagnosed with pancreatic cancer, we would like to help you collect compensation to cover your medical bills and provide financial support for you and your family. To find out if you qualify to file a Januvia cancer lawsuit, please contact us today.

Januvia® News

  • Januvia Sales Drop for the Quarter

    May 1st, 2013

    Sales of Merck's Januvia, a diabetes medication and the company's biggest seller, dropped for the first quarter of the year. The news, which was reported May 1, was surprising, Reuters said. Merck also lowered its full-year forecast today. Merck sales for the quarter dropped 9 percent to $10.7 billion, according to reports. That number is well below the $11.09 billion the market was expecting. The drug company... read more

  • Public Citizen Urges FDA to Ban Januvia Because of Cancer Risk

    April 15th, 2013

    Dr. Sidney Wolfe, Director of Public Citizen's Health Research Group, issued a statement last month, addressing the risk of precancerous changes in the pancreases of diabetic patients who use diabetes drugs Januvia (sitagliptin), Byetta (exenatide) and Victoza (liraglutide). According to the statement, Drs. Alexandra Butler and Peter Butler of the University of California, Los Angeles (UCLA) and colleagues published a study in the journal "Diabetes," showing... read more